390
Participants
Start Date
August 5, 2019
Primary Completion Date
August 31, 2025
Study Completion Date
May 13, 2028
prodisc C SK and/or Vivo
Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
Mobi-C Cervical Disc
Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
NYU Langone Orthopedic Hospital, New York
Hospital for Special Surgery, New York
Northwell Health, Lenox Hill Hospital, New York
Axis Neurosurgery and Spine, Williamsville
Penn State Milton S. Hershey Medical Center, Hershey
Georgetown University Hospital, Washington D.C.
University of Maryland Medical Center, Baltimore
M3-Emerging Medical Resarch, Durham
St. Vincent's Neurosurgery, Jacksonville
University of South Florida, Tampa
Florida Orthopaedic Institute, Temple Terrace
Kennedy-White Orthopaedic Center, Sarasota
Orthopaedic Institute of Western Kentucky, Paducah
SVCMC Solon Medical - Northern Ohio Surgery Center, Beachwood
Indiana Spine Group, Carmel
William Beaumont Hospital, Royal Oak
Spine Institute of Louisiana, Shreveport
Texas Back Institute, Plano
DFW Center for Spinal Disorders, Fort Worth
Texas Spine Care Center, San Antonio
HCA Healthcare, Lone Tree
Sky Ridge Medical Center Campus, Lone Tree
Center for Spine and Orthopedics, Scientific Education and Research Foundation, Thornton
The Disc Replacement Center, Salt Lake City
Flagstaff Bone and Joint, Flagstaff
Doctors Outpatient Center for Surgery, Los Angeles
Todd Lanman, MD, Inc., Beverly Hills
Sutter Health - Palo Alto Medical Foundation, Palo Alto
Sutter Health, Sacramento
University Spine Center, Wayne
Lead Sponsor
Centinel Spine
INDUSTRY